Breast cancer occurs when cells in breast begin to grow uncontrollably. Cancer cells usually form tumor and can be felt as a lump or seen under x-ray. Mostly, breast cancer begins in the duct that carries milk to the nipple, while some breast cancer cells start in the glands that make breast milk. As per National Institutes of Health (NIH), in the U.S., 14.6% of all new cancer cases diagnosed every year are of breast cancer. HER2 (human epidermal growth factor receptor 2) is a gene that plays a role in the development of breast cancer in most of the cases. Hence, breast cancer is categorized as HER2+ or HER2- depending on its involvement in the growth of breast cancer. HER2 receptors on breast cells control healthy growth and self-repair of breast cells, but in breast cancer, these genes mostly do not work correctly and signal cancer cells to make more HER2 receptors for HER2 proteins.
The drug candidates of breast cancer pipeline include, but are not limited to, BriaVax, U3-1402 and Oraxol. Some of the companies having drugs for breast cancer in pipeline are Eli Lilly and Company, F. Hoffmann-La Roche AG Takeda Pharmaceutical Limited, and Merrimack Pharmaceuticals, Inc.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.